Confluent starts pivotal anti-adhesion US trial:
This article was originally published in Clinica
Confluent Surgical has begun a pivotal trial in the US to assess its sprayable gel as a means of preventing pelvic adhesions following laparoscopic surgery in women. Early studies have shown that the product - SprayGel - remains in place as a barrier for five to seven days, the period when adhesions normally form, says the Waltham, Massachusetts firm. The company notes that adhesions are estimated to affect over two million women and men in the US, where the potential market for abdominopelvic adhesion management is $400-$500m. SprayGel is currently available in Europe and Australia.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.
Shares in Iovance Biotherapeutics have soared this week amid reports the US clinical-stage biotechnology company is in active M&A talks.